Novo Nordisk A/S Common Stock (NY:NVO)

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗

Topics Intellectual Property

February 12, 2026

The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts.

Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. ↗

February 12, 2026

Both companies are betting on interest in weight loss pills.

Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report ↗

February 12, 2026

Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs ↗

February 12, 2026

Novo Nordisk (NYSE: NVO) CEO Mike Doustdar said the company aims to reach about 15 million new patients when Medicare begins covering obesity treatments later this year.

Via Benzinga

HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In? ↗

February 11, 2026

Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly ↗

February 11, 2026

Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.

The Greenland Gambit: Inside the Transatlantic Tariff Shock and the Future of Arctic Sovereignty

Topics Intellectual Property

February 11, 2026

As of February 11, 2026, the global economy is navigating the aftershocks of a geopolitical standoff that nearly dismantled the post-war trade order. The "Greenland Tariff Escalation," a high-stakes...

Disney has hired a new CEO, with Josh D'Amaro taking over for Bob Iger in March.

Topics Bonds Economy Government

Disney Has Its Next CEO ↗

February 11, 2026

Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two high-yield healthcare stocks.

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. ↗

February 11, 2026

Big pharma and biotech take the earnings stage with reports from Eli Lilly and Novo Nordisk leading the lineup. Will they help the industry once again outperform AI champ Nvidia?

Biotech Beat Nvidia in 2025. Can It Do It Again? ↗

February 11, 2026

Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore ↗

Topics Artificial Intelligence

February 11, 2026

This stock has been known to soar after good news.

The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it.

Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know ↗

February 10, 2026

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

February 10, 2026

On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the...

Hoth Therapeutics's GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial ↗

Topics Artificial Intelligence Earnings Economy

February 10, 2026

The company announced positive preclinical results from a study evaluating GDNF as a potential treatment for obesity and metabolic-associated steatotic liver disease.

Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains? ↗

February 10, 2026

The stock has climbed in the triple digits over the past three years.

Today, Feb. 9, 2026, investors are reevaluating Hims & Hers after it pulled its weight-loss pill, facing legal action and FDA scrutiny.

Stock Market Today, Feb. 9: Hims & Hers Health Drops 16% on Novo Nordisk Lawsuit ↗

February 09, 2026

Hims & Hers Collapses After FDA Vows to Restrict Copycat GLP-1 Pill. Is the Stock Toast? ↗

Topics Artificial Intelligence Lawsuit Stocks

February 09, 2026

Hims & Hers could face difficulty in the future in selling copycat GLP-1 drugs.

These stocks have been going in opposite directions of late, but that doesn't mean that trend will continue.

Topics Intellectual Property Lawsuit

Novo Nordisk vs. Eli Lilly: What's the Better Long-Term Investment? ↗

February 09, 2026

Novo Nordisk is suing Hims & Hers -- but Hims & Hers already surrendered.

Topics Intellectual Property

Why Novo Nordisk Stock Just Popped ↗

February 09, 2026

Everyone's ganging up on Hims & Hers stock this week.

Topics Intellectual Property Lawsuit

Why Hims & Hers Stock Just Got Destroyed ↗

February 09, 2026

The GLP-1 Gold Rush Hits a Wall: Novo Nordisk Sues Hims & Hers as FDA Crackdown Triggers 20% Stock Crash

Topics Lawsuit

February 09, 2026

The multi-billion dollar weight-loss drug market experienced a seismic shift this morning as the era of easy-access compounded alternatives faced its most significant legal and regulatory challenge to...

According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.

Topics Intellectual Property Lawsuit

FDA Says Novo's Wegovy Pill TV Advertisement Is Misleading: NVO Stock Pares Gains ↗

February 09, 2026

Novo Nordisk just did Eli Lilly stock a huge favor.

Topics Lawsuit

Why Eli Lilly Stock Just Popped ↗

February 09, 2026

The GLP-1 Gold Rush Hits a Wall: Hims & Hers Shares Crater After Abrupt Oral Wegovy U-Turn

Topics Lawsuit

February 09, 2026

The meteoric rise of telehealth giant Hims & Hers Health (NYSE: HIMS) faced its most severe reckoning this week, as the company’s stock plummeted to a one-year low following a dramatic withdrawal of...

Novo Nordisk Sues Hims & Hers Over Compounded Wegovy, Calls For Permanent Sales Ban: HIMS Stock Tanks ↗

Topics Earnings Intellectual Property

February 09, 2026

Novo stated that it has filed the lawsuit to protect its intellectual property and the American public.

HIMS Stock In Turmoil: Retail Bulls Bet On Rebound, Skeptics See Bloodbath After Compounded Weight-Loss Pill Halt ↗

Topics Intellectual Property Lawsuit

February 08, 2026

Retail bulls pointed to similar price levels during high short interest in late 2024 and said ending compounded sales removes the risk of a costly legal fight.

Novo Nordisk has good news and bad news to report in its fourth-quarter 2025 earnings.

Topics Intellectual Property Law Enforcement

Novo Nordisk Plunges Nearly 15% After Earnings. Here's What Investors Need to Know. ↗

February 08, 2026

Medicare Changes in 2026 Every Retiree Needs to Know: The Good, the Bad, and the Ugly ↗

February 08, 2026

Retirees should brace themselves for both positive and negative changes to Medicare this year.

Eli Lilly is the leader in the GLP-1 space, but here's another GLP-1 stock and a medical device maker to consider.

Topics Economy Government Retirement

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon. ↗

February 07, 2026